SeaStar Medical Advances Pipeline, Hits Key Milestones in AKI Treatments
Event summary
- SeaStar Medical added 13 new top-rated children’s hospitals to its QUELIMMUNE pediatric AKI customer base, bringing the total to 16.
- Completed enrollment in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry with 50 patients.
- Exceeded 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial for adult AKI patients.
- Initiated a cardio-renal clinical trial to expand the SCD therapy's applications.
- Reported $1.2 million in net revenue for 2025, up from $135 thousand in 2024.
The big picture
SeaStar Medical is strategically positioning itself to leverage its breakthrough SCD therapy across multiple indications, moving beyond the pediatric AKI market into the larger adult AKI and cardio-renal sectors. The company's focus on regulatory efficiency and market expansion reflects broader industry trends toward targeted immunotherapies for critical care conditions. With a strengthened balance sheet and key milestones achieved, SeaStar Medical is poised to capitalize on the significant unmet needs in these high-mortality patient populations.
What we're watching
- Regulatory Pathways
- The pace at which SeaStar Medical can navigate the FDA's modular PMA submission process for the adult AKI indication will determine the timeline for market expansion.
- Market Adoption
- Whether SeaStar Medical can sustain the momentum in QUELIMMUNE adoption among top-ranked children’s hospitals and achieve the anticipated $2 million in net product revenue in 2026.
- Pipeline Expansion
- The success of the NEUTRALIZE-CRS clinical trial in treating patients with chronic heart failure and cardiorenal syndrome, which could open new revenue streams.
Related topics